MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more

Location: 444 West Lake Street, Chicago, IL, 60606, United States | Website: https://maiabiotech.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

49.82M

52 Wk Range

$1.40 - $3.74

Previous Close

$1.51

Open

$1.48

Volume

120,765

Day Range

$1.46 - $1.50

Enterprise Value

39.68M

Cash

10.14M

Avg Qtr Burn

-3.943M

Insider Ownership

21.43%

Institutional Own.

6.92%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
THIO Details Non-small cell lung carcinoma, Cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ateganosine Details Non-small cell lung carcinoma, Cancer, Hepatocellular carcinoma, Small cell lung cancer, Colorectal cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.